FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
GLP-1 questions emerge for 2025
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...
It’s getting harder to claim success with weight reduction drugs
Novo Nordisk’s obesity drug CagriSema’s test results showed an average weight loss of over 20%, but its stock slid in ...
Walla Walla Union Bulletin23hOpinion
Commentary: The bar for successful obesity drugs is rising
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...
Novo Nordisk A/S (NVO): A Bull Case Theory
We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...
Study suggests estrogen may trigger binge drinking
The female hormone estrogen appears to promote binge drinking in women, a new mouse study published recently in the journal ...
Weight-loss drug investments: why 2025 could be a game-changer
Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped ...
ABC30 Action News17h
News Feed
At 40, LeBron says he could play at high level 5 to 7 more years --... Updated 4 minutes ago LeBron James, who celebrated his 40th birthday Monday, says he could play at a high level for "another ...